Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications
- 30 June 1990
- journal article
- review article
- Published by Elsevier in Human Immunology
- Vol. 28 (2), 198-207
- https://doi.org/10.1016/0198-8859(90)90020-p
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1989
- The T-Cell Receptor Repertoire and Autoimmune DiseasesAnnual Review of Immunology, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.The Journal of Experimental Medicine, 1988
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsNew England Journal of Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findingsJAMA, 1986
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Reconstitution of an active surface T3/T-cell antigen receptor by DNA transferNature, 1985